Transcode Therapeutics, INC Schedule 13G passive stakes

Unleash Immuno Oncolytics, Inc. has filed a Schedule 13G, reporting beneficial ownership of 300,000 shares, representing 9.94% of the outstanding common stock of TransCode Therapeutics, Inc.

Elena Rosa Braci has filed a Schedule 13G, reporting beneficial ownership of 186,236 shares, representing 6.17% of TransCode Therapeutics, Inc.'s common stock.

Daniel Eduardo Katzman has reported beneficial ownership of 155,611 shares, representing 5.16% of the outstanding common stock of TransCode Therapeutics, Inc.

Yorkville Advisors and affiliates have reported a 9.9% beneficial ownership stake in TransCode Therapeutics following a convertible note purchase.

Sabby Management, Sabby Volatility Warrant Master Fund, and Hal Mintz have jointly disclosed a passive 4.9% beneficial ownership in Transcode Therapeutics, Inc. common stock.

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC reported a passive beneficial ownership of 82 shares, representing 0.0% of Transcode Therapeutics Inc. common stock.

Anson Funds Management LP and related entities reported a passive 0.1% beneficial ownership stake in Transcode Therapeutics, Inc. as of June 30, 2025.

The Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have disclosed a 5.9% beneficial ownership stake in Transcode Therapeutics, Inc.

Anson Funds Management LP and affiliated entities have disclosed a 9.9% beneficial ownership stake in Transcode Therapeutics, Inc., comprising 113,479 shares of common stock.

Sabby Management, LLC, Sabby Volatility Warrant Master Fund Ltd, and Hal Mintz have jointly disclosed a 9.9% passive beneficial ownership stake in Transcode Therapeutics, Inc. common stock.